Biological sciences/Cell biology/Organelles/Mitochondria
[URI /631/80/642/333]
Biological sciences/Cell biology/Cell death/Apoptosis
[URI /631/80/82/23]
Biological sciences/Cell biology/Cell death/Necroptosis
[URI /631/80/82/2344]
Biological sciences/Immunology/Inflammation
[URI /631/250/256]
Biological sciences/Cell biology/Cell signalling/Stress signalling
[URI /631/80/86/2366]

Article series: Cell death

Mitochondria as multifaceted regulators of cell death

Florian J. Bock and Stephen W.G. Tait*

Cancer Research UK Beatson Institute, Institute of Cancer Sciences, Garscube Estate, Glasgow, G61 1BD, U.K.

*Corresponding author: stephen.tait@glasgow.ac.uk

Abstract

Through their many and varied metabolic functions, mitochondria power life. Paradoxically, mitochondria also have a central role in apoptotic cell death. Upon induction of mitochondrial apoptosis, mitochondrial outer membrane permeabilization (MOMP) usually commits a cell to die. Apoptotic signalling downstream of MOMP involves cytochrome *c* release from mitochondria and subsequent caspase activation. As such, targeting MOMP in order to manipulate cell death holds tremendous therapeutic potential across different diseases, including neurodegenerative diseases, autoimmune disorders and cancer. In this Review, we discuss new insights into how mitochondria regulate apoptotic cell death. Surprisingly, recent data demonstrates that besides eliciting caspase activation, MOMP engages a variety of pro-inflammatory signalling functions. As we highlight, together with new findings demonstrating cell survival following MOMP, this pro-inflammatory role suggests that mitochondria-derived signalling downstream of pro-apoptotic cues may also have non-lethal functions. Finally, we discuss the importance and roles of mitochondria in other forms of regulated cell death, including necroptosis, ferroptosis and pyroptosis. Collectively, these new findings offer exciting, unexplored opportunities to target mitochondrial regulation of cell death for clinical benefit.

[H1] Introduction

Mitochondria are essential for life. Positioned at the heart of cellular metabolism, they serve a key role in ATP generation via oxidative phosphorylation. Beyond their many core metabolic functions, mitochondria are implicated in an expanding array of cellular processes, ranging from inflammation to regulation of stem cell generation [1,2]. What may seem as a paradox, mitochondria are often essential for cell death.

Regulated cell death underpins health; for example, inhibition of cell death promotes cancer and auto-immunity whereas excessive cell death contributes to neurodegenerative diseases, including Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis and Huntington disease. Consequently, considerable interest has centred upon targeting of mitochondria to manipulate cell death in disease. Validating this rationale, recently developed anti-cancer drugs called BH3-mimetics **[G]** sensitize cells to mitochondrial-dependent death, displaying potent anti-tumour activity [3,4]. The role of mitochondria in cell death is unequivocally established in apoptosis, where mitochondrial outer membrane permeabilization (MOMP) driven by effector pro-apoptotic members of the BCL-2 family of proteins (prominently BAX and BAK; **Box 1**) initiates a signalling cascade that leads to cell death; although, as we have now become to appreciate, induction of MOMP is not synonymous with apoptosis and commitment of a cell to die is not definitive downstream of MOMP. In addition, MOMP has other consequences beyond execution of cell death, including induction of pro-inflammatory signalling. Finally, while apoptosis is a major form of regulated cell death, it is by no means the only one. More recently described regulated cell death modalities include necroptosis, pyroptosis and ferroptosis. Mitochondria have also been implicated in these additional modalities of regulated cell death, but their roles are still poorly defined and appear less conspicuous.

In this Review we discuss how mitochondria contribute to regulated cell death, placing this contribution in the context of health and disease. Specifically, we highlight new insights into how mitochondria initiate apoptosis, and discuss their parallel role in eliciting pro-inflammatory signalling activity with important consequences for physiology. Taken together with recent studies showing heterogeneity in MOMP between mitochondria within a cell treated with pro-apoptotic stimuli, we highlight that mitochondrial permeabilization

can exert various non-lethal signalling functions. We then discuss the contribution of mitochondria to more recently described types of regulated cell death, highlighting mitochondria as a central nexus between different cell death modalities.

[H1] Mechanisms of mitochondrial apoptosis

Apoptotic cell death is a major form of regulated cell death that has central roles in many processes ranging from embryonic development to immune homeostasis [5] . As we now discuss, in many instances, mitochondria are crucial for the initiation of apoptosis.

[H2] Apoptotic signalling.

There are two main apoptotic signalling pathways: the extrinsic (also called death-receptor) and the intrinsic, or mitochondrial, pathways of apoptosis (**Figure 1**). Both converge upon activation of caspase 3 and caspase 7. As proteases, these executioner caspases cleave hundreds of different proteins causing the biochemical and morphological hallmarks of apoptosis [6]. The extrinsic pathway is activated at the plasma membrane by death receptor ligands binding to their cognate receptors, leading to activation of caspase 8 (a component of a complex known as the death inducing signalling complex (DISC) **[G]**) [7]. Active caspase 8 propagates apoptosis by cleaving the pro-caspase 3 and pro-caspase 7, causing their activation (**Figure 1**).

Diverse cellular stresses, for instance growth-factor deprivation or DNA damage, kill by the mitochondrial pathway of apoptosis. The mitochondrial pathway requires MOMP to release soluble proteins from the mitochondrial intermembrane space leading to cell death (**Figure 1**). Amongst these intermembrane space proteins, cytochrome *c* — an essential component of the electron transport chain — binds the adaptor molecule APAF-1 forming a complex called the apoptosome [8,9]. The apoptosome, in turn, binds to and activates the initiator caspase 9, which subsequently cleaves and activates the executioner caspases. MOMP also causes the release of proteins including SMAC **[G]** and OMI **[G]** that block the caspase inhibitor XIAP **[G]** , facilitating apoptosis. The extrinsic apoptotic pathway crosstalks to the mitochondrial pathway by caspase 8-mediated cleavage of BID, a pro-apoptotic BH3-only member of the BCL-2 family (**Box 1**) , which generates tBID that potently induces MOMP (**Figure 1**).

With some notable exceptions that we will later discuss, MOMP typically commits cells to death, even in the absence of caspase activity (this phenomenon is known as caspase-independent death). Thus, MOMP is considered a point-of-no-return in apoptosis execution [10-12]. Consistent with MOMP being the point of commitment to cell death, mice deficient in caspase activity associated with the mitochondrial pathway of apoptosis (e.g. *APAF-1*$^{-/-}$ and *caspase-9*$^{-/-}$) display much milder developmental defects than MOMP-inhibited (*BAX*$^{-/-}$, *BAK*$^{-/-}$) mice [13-18]. The reason for MOMP being able to mediate caspase-independent cell death is overall metabolic catastrophe, related to the fact that often all mitochondria undergo MOMP during apoptosis [19] and their progressive dysfunction following MOMP causes widespread ATP loss [20]. Because MOMP serves to commit a cell to die, it is tightly regulated, primarily by members of the BCL-2 protein family (**Box 1**).

[H2] Mechanisms of MOMP.

During mitochondrial apoptosis, activation of the pro-apoptotic effectors BAX and BAK is usually essential for MOMP and cell death [21]. BAX and BAK are largely considered redundant because only upon their combined loss are cells resistant to mitochondrial apoptosis and extensive developmental defects are observed [16,17,21]. Nevertheless, differences for BAX versus BAK in mitochondrial apoptosis have been reported in some studies [22,23]. For example, BAX and BAK display a differential requirement for the mitochondrial porin VDAC2 in their ability to induce apoptosis: while VDAC2 associates with both proteins, VDAC2 is required for BAX, but not BAK, to induce apoptosis [24-26]. Importantly, such differences can govern the effectiveness of chemotherapy responses that often require mitochondrial apoptosis [22].

In healthy cells, BAX localises to the cytoplasm and BAK to the mitochondria, however, both can shuttle between the mitochondria and cytoplasm [27-29] (**Figure 2**). Under basal conditions BAX and BAK are inactive. Following activation, BAX accumulates at the mitochondria. BAX and BAK can be directly activated by binding a subclass of BH3-only proteins called direct activators (BID, PUMA and BIM) [30]. Structural studies have demonstrated that the direct activator BH3-domain binds within the hydrophobic groove of BAX and BAK, leading to extensive conformational changes allowing activation [31-33]. This structural information has guided the development of modified BH3-peptides derived from

BH3-only proteins that block BAK activation, providing proof-of-concept for therapeutic targeting of this step to block cell death [34].

Experiments with chemically stabilised BH3-peptides also enabled a discovery of a second BH3-binding site in BAX[35]. This second BH3-binding site is distant from the BAX hydrophobic groove, located in the amino-terminus of the protein, and it promotes BAX activation through an allosteric conformational change [35,36]. Notably, BAX-activating small molecules that target this amino-terminal site and promote BAX activation display potent anti-tumour activity [37]. Reconciling a requirement for two activation sites, recent data supports a sequential model of BAX activation in which BH3-proteins first bind the amino-terminal site, facilitating BH3-binding to the hydrophobic groove for full BAX activity [38]. Of note, there is evidence that BH3-only proteins are not absolutely essential for BAX and BAK activation (see **Box 1**). During activation, BAX and BAK expose their BH3-domains that can further propagate their own activity [36,39]. Once activated, BAX and BAK homodimerize and these dimers, form higher-order oligomers that are essential for MOMP [40-44] (**Figure 2**).

How do active BAX and BAK permeabilize the mitochondrial outer membrane, initiating cell death? Consensus to this long-standing question centres on activated BAX and BAK inducing lipidic (toroidal) pores in the mitochondrial outer membrane (**Figure 2**). Such lipidic pores are formed by fusion of the inner and outer leaflets of membranes, which is promoted and stabilised by protein insertion. Indeed, studies using synthetic liposomes and mitochondrial outer membrane-derived vesicles demonstrate that BAX can induce large (>100nm) membrane pores visible by cryo-electron microscopy that grow over time [45,46]. Moreover, BAX pores are tuneable in size dependent on BAX concentration [46]. Importantly, super-resolution microscopy has enabled direct visualisation of BAX-mediated pores in apoptotic cells [47,48]. On apoptotic mitochondria, BAX localises in heterogenous ring-like structures, roughly approximating in size to holes observed in mitochondrial outer membrane-derived vesicles. Formation of such rings on apoptotic mitochondria was associated with membrane permeabilization, further supporting permeabilization of the mitochondrial outer membrane via lipidic pore formation[47].

Extensive genetic and biochemical data firmly establish BAX and BAK as central effectors of MOMP. However, other proteins can also cause MOMP. Particular interest has focused on BOK, a BAX/BAK-like BCL-2 protein, since recent studies have demonstrated that BOK can induce MOMP and cell death in the absence of BAX and BAK [49,50]. Genetic support for this comes from the finding that BOK deficiency exacerbates the developmental defects observed in *Bax*$^{-/-}$ *Bak*$^{-/-}$ double knock out mice [16]. Nevertheless, BOK induced MOMP differs from classical BAX/BAK-dependent MOMP in many ways. For instance, unlike BAX and BAK, the pro-apoptotic activity of BOK does not appear to be regulated by BCL-2 proteins in any way [49,51]. In vitro liposome and mitochondrial permeabilization assays demonstrate that BOK is inherently active [49,52]. This constitutive activity relates to the intrinsic instability of the BOK hydrophobic core such that it can mediate MOMP independent of BH3-only proteins[52]. Consistent with BOK having constitutive pro-apoptotic activity, in healthy cells BOK undergoes ER associated degradation **[G]** (ERAD) that maintains it at low levels [49]. However, because BOK is expressed in many healthy tissues, additional regulatory mechanisms must exist to counter its pro-apoptotic activity [53].

Non-BCL-2 family proteins can also induce MOMP. Specific members of the gasdermin protein family exhibit pore-forming activity upon cleavage. As we will discuss later, cleavage of Gasdermin D (GSDMD) is essential for an inflammatory type of cell death called pyroptosis. During mitochondrial apoptosis, caspase 3-mediated cleavage of Gasdermin E (GSDME, also called DFNA5) liberates a pore-forming amino-terminal fragment that can promote plasma membrane permeabilization during apoptotic cell death [54,55]. GSDME mediated plasma membrane permeabilization induces a necrotic-like cell death that has been proposed to contribute to the chemotherapy-associated toxicity [54]. This GSDME amino-terminal cleavage fragment can also localise to the mitochondria and cause MOMP [56]. In this manner, GSDME is proposed to elicit a feed-forward mechanism that enhances caspase activation during apoptosis. In an analogous manner, during pyroptosis, the GSDMD amino-terminal cleavage fragment can also induce MOMP [56] (see also below). Although requiring further investigation, given their established pore-forming properties, the amino-terminal fragments of gasdermins likely directly permeabilize mitochondria independently of BAX and BAK.

[H2] Dynamics of MOMP.

Independent of apoptotic stress, MOMP is usually rapid and complete — all mitochondria undergo MOMP over a ten-minute window [19,57]. Emphasising an earlier point, the extensive nature of MOMP is likely central to it being a point-of-no-return in apoptotic commitment. High-speed imaging of mitochondrial apoptosis has shown that MOMP can initiate at a discrete sub-population of mitochondria, before progressing in a wave-like manner across all the mitochondria in the cell [58-60]. Using frog egg extracts in vitro, MOMP has been found to propagate between mitochondria as a trigger wave, maintaining constant speed and amplitude over a long distance; this may facilitate the execution of apoptosis in large cells such as neurons [61].

Why is MOMP rapid and extensive? One model proposes that MOMP initiates a caspase-dependent feed forward loop, possibly by caspase-mediated BID cleavage that promotes further MOMP. However, while caspase-activity supports MOMP trigger wave propagation in vitro, blocking caspase activity following a mitochondrial apoptotic stimulus neither impacts on the kinetics nor on the extent of MOMP in cells [19]. Furthermore, inhibiting caspase activity following a mitochondrial apoptotic stimulus usually doesn't protect against cell death. These findings argue against an important role for caspase activity in amplifying MOMP. Other proposed mechanisms include reactive oxygen species (ROS)-dependent feed-forward propagation of MOMP, although how ROS promotes this remains unclear [62] Perhaps the most likely explanation centres on the ability of active BAX and BAK to activate further BAX and BAK molecules [36,39]. Akin to falling dominos, this would be predicted to rapidly and extensively drive MOMP.

[H2] Inner mitochondrial membrane remodelling during apoptosis.

Soluble mitochondrial intermembrane space proteins are released following MOMP irrespective of protein size [63]. However, some studies have shown that the release of cytochrome *c* can be further regulated even following MOMP, affecting caspase activation and apoptosis [64-68]. This is because the majority of cytochrome *c* resides within mitochondrial cristae — dynamic inner mitochondrial membrane folds that harbour electron transport chain components. Cristae accessibility to the intermembrane space is regulated by cristae junctions [69]. As such, cytochrome *c* has been proposed to be trapped

within cristae in healthy cells, necessitating widening of the cristae junctions in order to allow efficient cytochrome *c* release. Indeed, following MOMP, extensive cristae remodelling has been observed. How is this regulated? Mitochondria are dynamic organelles that constantly undergo cycles of fission and fusion. Immediately following MOMP, extensive mitochondrial fragmentation occurs at mitochondrial–endoplasmic reticulum (ER) contact sites [70], which requires the mitochondrial fission protein DRP-1 [59,67]. Although dispensable for MOMP [71,72], DRP-1 promotes cristae remodelling, which has been proposed to facilitate cytochrome *c* release. Several reports suggest that remodelling occurs via the effect of DRP-1 on the GTPase OPA1. In the intermembrane space, OPA-1 regulates inner mitochondrial membrane fusion and cristae junction size: oligomers of OPA-1 keep junctions narrow, whereas OPA-1 oligomer disassembly widens the junctions [71]. Following MOMP, OPA-1 is cleaved by different intermembrane space proteases including OMA1, leading to oligomer disassembly and junction opening [73-75]. During apoptosis, DRP-1 is modified with the ubiquitin-like protein SUMO, leading to the stabilization of the mitochondrial–ER membrane contact sites. This promotes calcium influx into the mitochondria from the ER, which has been shown to be required for cristae remodelling [70]. However, it has also been shown that cristae remodelling mediated by DRP-1 during apoptosis is independent of OPA-1 and that OPA-1 oligomers can disassemble even in the absence of DRP-1 (ref. [76]).

Regardless of the exact mechanism, the importance of inner membrane remodelling for mitochondrial apoptosis is controversial. For instance, some studies have shown that inhibiting components of the cristae remodelling machinery (e.g. DRP-1) has minimal effect upon the release of cytochrome *c*, caspase activation and apoptosis [71,72]. Secondly, inner mitochondrial membrane remodelling has been reported to occur as a secondary consequence of caspase activation [77]. Irrespective of caspase activity, inner mitochondrial membrane remodelling occurs subsequent to MOMP. Thus, similar to caspase inhibition, blocking inner mitochondrial membrane remodelling wouldn't be expected to prevent cell death unless cells can somehow survive MOMP — an area we will now discuss.

[H1] Surviving MOMP

Although MOMP is considered the point-of-no-return in mitochondrial apoptosis, some exceptions exist, where MOMP occurs to varying degrees with wide-ranging effects,

beyond lethality, downstream of apoptotic stimuli. It is also now evident that cells are able to survive MOMP, which can have important impact on physiology. Our discussion centres on how cells can survive MOMP in three distinct settings: widespread MOMP under caspase inhibited conditions; limited MOMP; and widespread mitochondrial permeabilization accompanied by effector caspase activity.

[H2] MOMP can be heterogeneous, permitting survival and signalling functions.

MOMP was originally defined as an all-or-nothing event. However, more recently, it has been shown that the cells can survive MOMP under caspase-inhibited conditions — when cleavage of cellular components is prevented — and the key to cell survival is the maintenance of metabolic activity. Glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can promote cell survival following MOMP, which is dependent on its well-established glycolytic role in ATP synthesis and through its ability to transcriptionally stimulate autophagy to remove permeabilized and hence, non-functional, mitochondria via mitophagy [78]. Survival under these conditions also tightly correlates with the presence of intact mitochondria that evaded MOMP, a condition termed incomplete MOMP [79]. These intact mitochondria serve as critical pool to re-establish mitochondrial network in the cell, permitting cell survival (**Figure 3a**).

Although further studies in this area are needed, it is likely that incomplete MOMP underpins survival in various cell contexts. In support of this, following nerve growth factor (NGF) deprivation, sympathetic neurons undergo MOMP, but under conditions of caspase inhibition, NGF re-addition restores intact mitochondria in these neurons to enable cell survival [80,81].

Variable MOMP is also observed in response to sub-lethal apoptotic stresses triggered by low doses of cytotoxic drugs like BH3-mimetics or proteasome and mitotic inhibitors. However, in this case only a small fraction of mitochondria undergoes MOMP without the execution of cell death, a condition called minority MOMP[82] (**Figure 3b**). While minority MOMP doesn't kill cells, it still engages caspase activity. To permit survival, caspase activity is likely restrained by multiple mechanisms, including degradation of cytochrome *c* upon MOMP leading to reduced caspase activity [83], lowered affinity of active (cleaved)

caspase 9 for the apoptosome[83,84], restriction of caspase localization [85], their turnover [86] or expression of inhibitors to dampen their activity [87].

Minority MOMP-induced caspase activity likely has both positive and negative consequences. Apoptosis has well-established anti-cancer activity, for instance the tumour suppressor p53 engages apoptosis to prevent cancer, and anti-cancer treatments often kill cancer cells through apoptosis. Nevertheless, different studies argue that apoptotic signalling also has pleiotropic oncogenic effects [88]. Along these lines, minority MOMP causes caspase-dependent DNA damage and genomic instability, promoting cellular transformation[82]. The DNA damaging effects of minority MOMP require activation of caspase-activated DNAse (CAD) [82]. Following sub-lethal stress, caspase 3-dependent release of endonuclease G (Endo G) from the mitochondria can also cause DNA damage [89]. DNA-damaging effects of sub-lethal caspase activity have also been reported following diverse apoptotic stimuli, encompassing extrinsic and intrinsic apoptotic triggers [90-92]. By affecting genome integrity, minority MOMP might impact on cancer in different ways, for instance by enhancing its initiation or by promoting the evolution of resistance to apoptosis-inducing therapies (**Figure 3b**). However, tumour mutational load resulting from DNA damage is also responsible for the generation of so called neoantigens **[G]**, which correlate with the activation of anti-tumour immunity. As proposed elsewhere [93], potentially the DNA-damaging effects of minority MOMP could also have beneficial effects in cancer therapy by increasing neoantigen generation.

At face value, effects of minority MOMP in cancer appear more of an unwanted glitch of the mitochondrial apoptotic pathway, but does minority MOMP have any physiological roles? Because it permits caspase activity without cell death, minority MOMP is ideally suited to initiate non-lethal caspase signalling , which has been implicated in wide-ranging cellular functions such as differentiation and proliferation[94]. Furthermore, as we discuss in more detail in the following section, MOMP is also a potent inductor of inflammatory signalling. In this context, a recent study has shown that minority MOMP can engage innate immune signalling pathways (both caspase-dependent and independent) that inhibit the growth of diverse intracellular pathogens[95] (**Figure 3b**). Dissecting the functions for minority MOMP remains a major challenge, mostly because it shares the same initiating

machinery as mitochondrial apoptosis (centring on BAX/BAK activation). Because caspase substrates downstream of MOMP are dispensable for cell death, where relevant (e.g. CAD in DNA damage) specific analysis of these substrates should allow genetic definition of minority MOMP functions in vivo.

Besides identifying physiological functions of mitochondrial heterogeneity in the event of MOMP, several key mechanistic questions remain to be answered. Most importantly, why some mitochondria selectively permeabilize and how do these mitochondria differ compared with those that remain intact? Some level of regulation presumably exists, as exemplified by the physiological role of minority MOMP in pathogen defence. One observation is that in the context of incomplete MOMP, intact mitochondria had higher levels of anti-apoptotic BCL-2 proteins associated with them. Accordingly, neutralisation of anti-apoptotic BCL-2 function (by BH3-mimetic treatment) converted incomplete MOMP to complete MOMP, thereby impeding cell survival [79].

[H2] Cell recovery via anastasis.

To permit survival following extensive MOMP, ideally a cell would require prevention of caspase activation coupled to a means of generating (or retaining) non-permeabilized mitochondria. However, recovery from a full-scale apoptosis has been described in mammalian HeLa cells exposed to ethanol and called anastasis (Greek for 'rising to life')[96]. Generally, ethanol induces MOMP and caspase activation. Intriguingly, removal of ethanol after caspase activation allowed recovery of intact mitochondria in some cells that enabled cell survival and proliferation. This recovery was rapid and within 24 hrs following removal of the apoptotic stimulus the entire mitochondrial population was reinstated. Survival under these conditions was associated with increased genomic instability, suggesting that anastasis may be oncogenic[96]. Anastasis was also associated with a specific transcriptional response programme that led to increased migratory capacity of recovered cells [97].

Overall, anastasis defies the dogma that MOMP and extensive caspase activity commits a cell to die. While fascinating, it also poses a number of challenging questions. Firstly, how can a cell withstand such extensive caspase activity, causing widespread cleavage of subcellular substrates, yet survive? Secondly, why is the persistence of initiating apoptotic stimulus (in this case ethanol) required for death even following MOMP initiation

of caspase activity? Thirdly, how does the mitochondrial population recover so quickly following MOMP? Given the rapidity of mitochondrial recovery and a requirement to remove MOMP-inducing stimulus to enable cell survival, does this suggest that MOMP may even be reversible in some situations? Further supporting a reversible nature of MOMP, a recent study reported a chemical inhibitor of mitochondrial apoptosis called compound A that blocks cell death downstream of BAX activation[98]. Compound A exerts cytoprotective function by targeting succinate dehydrogenase subunit B (SDHB) — a critical component of complex II in the electron transport chain. This cytoprotective effect is related to inner mitochondrial membrane remodelling discussed above. By binding SDHB, compound A maintains electron transport chain function following BAX activation, which is proposed to inhibit OMA1 protease activity — by preventing generation of ROS, which could activate OMA1— and in doing so blocking OPA1 processing, inner mitochondrial membrane remodelling and extensive cytochrome *c* release. However, an alternative explanation may be that Compound A prevents MOMP from initially occurring downstream of activated BAX. Irrespective of its cytoprotective mechanism, in vivo administration of Compound A displayed beneficial effects in a rat model of Parkinson disease: it reduced the death of dopaminergic neurons and prevented the onset of Parkinson-like behaviour, implying that neuronal functionality, at least in the short-term, is maintained[98]. Compound A may represent a basis to develop therapeutic inhibitors of the mitochondrial apoptotic pathway.

[H1] MOMP and inflammation

The textbook view of apoptosis is that it is a non-inflammatory, silent form of cell death [99]. Intuitively this makes perfect sense — billions of cells in our bodies undergo mitochondrial apoptosis on a daily basis [100]. Despite this common view, recent research has shown that the apoptosis-initiating event, MOMP, is inherently pro-inflammatory (**Figure 4**).

[H2] Mechanisms and consequences of MOMP-driven inflammatory signalling.

Pro-inflammatory effects of MOMP were first observed under conditions of caspase 9 deficiency, most likely because these cells show delayed death allowing inflammation to be detected [101,102]. A consequence of increased inflammation in caspase 9-deficient mice was that these mice displayed enhanced resistance to viral infection and impaired haematopoietic stem cell function [101,102]. Both phenotypes are associated with a type I

interferon **[G]** (IFN) response that is induced by cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) signalling. The cGAS–STING signalling pathway is a key innate immune pathway that senses double-stranded DNA (dsDNA) — mostly foreign, coming from bacteria or DNA viruses — to drive inflammation[103]. Upon DNA binding, cGAS catalyses the reaction of ATP and GTP to generate the secondary messenger, cyclic guanosine monophosphate–adenosine monophosphate (cGAMP). cGAMP binds to and activates the adaptor protein STING, which subsequently activates TBK1 kinase. TBK1 phosphorylates and activates the transcription factor IRF3 as well as NF-κB leading to a type I interferon expression.

BAX and BAK were found to be required for MOMP-induced cGAS–STING activity, but surprisingly, so was mitochondrial DNA (mtDNA), suggesting that mtDNA is recognized by cGAS–STING in the context of apoptosis, providing basis for inflammatory signalling. This was unexpected because cGAS and STING reside outside the mitochondria, whereas mtDNA localises to the mitochondrial matrix and the inner mitochondrial membrane was thought to remain intact during apoptosis. Various studies employing different imaging approaches in murine embryonic fibroblasts as well as various cancer cell lines have addressed how mtDNA could be exposed to cGAS–STING[104-106]. Super-resolution imaging of cells undergoing mitochondrial apoptosis demonstrated that MOMP induction is followed, over time, by the formation of expanding pores on the mitochondrial outer membrane. These large pores, called macropores, were decorated with activated BAX at their edges[104,105], suggesting that BAX-mediated membrane permeabilization progresses over time causing widening of these outer mitochondrial membrane pores. Similar BAX/BAK-dependent progressive membrane permeabilization has been previously reported in liposomes [46]. These macropores allowed extrusion of the inner mitochondrial membrane, which in some cases was associated with permeabilization of the membrane at such extrusions; this would allow mtDNA release and cGAS–STING activation (**Figure 2**). Whether inner mitochondrial membrane permeabilization is regulated remains unclear. Although the underlying mechanism remains unknown, we know that it is independent of DRP-1-mediated mitochondrial fission [104,105]. Furthermore, compared with healthy mitochondria, the matrix of apoptotic mitochondria is more dilute [106]. Potentially, the extra pressure associated with the increased volume of a

more dilute matrix may be an important driver of both macropore expansion and inner mitochondrial membrane extrusion and subsequent rupture.

By allowing mtDNA release, inner mitochondrial membrane permeabilization may be an important initiator of inflammation in different areas of health and disease. One example is Parkinson disease, which is associated with defective mitochondrial clearance — through a selective autophagy process called mitophagy — that in the case of early-onset Parkinson disease is caused by the loss of mitophagy regulators: the E3 ubiquitin ligase Parkin or its upstream mitochondrial kinase, PINK1. Loss of PINK1 or Parkin has been found to activate cGAS–STING signalling, most likely by mtDNA released from defective mitochondria that are not cleared by mitophagy, leading to an inflammatory phenotype [107]. Underscoring the functional importance of this inflammatory response, deletion of STING prevents inflammation in Parkin-deficient mice, inhibiting the death of dopaminergic neurons and Parkinson-like behavioural defects [107] . Beyond driving Parkinson disease, cytosolic mtDNA has various other documented roles in inflammation and immunity, although how mtDNA is released to the cytoplasm in those different contexts remains unclear [108-110]. In many of these instances, mtDNA dependent activation of inflammation occurs without cell death; it is possible that damaged mitochondria promote the activation of BAX/BAK, leading to inner mitochondrial membrane permeabilization downstream of MOMP as discussed above. Should BAX or BAK be required for mtDNA release in these circumstances, it must occur under conditions of minority MOMP. Relating this to our earlier discussion, the ability of minority MOMP to mediate pathogen clearance is, in part, due to mtDNA dependent activation of cGAS–STING [95].

Besides mtDNA dependent activation of cGAS–STING, MOMP engages additional pro-inflammatory signalling pathways (**Figure 4**). Under caspase deficiency, MOMP caused downregulation of inhibitors of apoptosis proteins (IAPs), such as cIAP1 and cIAP2. This, in turn, upregulated the kinase NIK leading to NF-κB activation[111]. This mechanism is analogous to that previously observed with SMAC-mimetic compounds **[G]** [112,113]. Like SMAC mimetics, MOMP can trigger NF-κB-dependent production of tumour necrosis factor (TNF) that, co-incidentally, can trigger an alternative form of cell death called necroptosis

458 (discussed later) following MOMP [111]. Nevertheless, how MOMP triggers IAP depletion is
459 unclear. While it requires the ability of cIAP1 to bind to SMAC-like proteins, combined
460 genetic deletion of SMAC and OMI (another IAP binding protein) does not prevent cIAP
461 degradation following MOMP. IAP degradation independent of SMAC and OMI may be due
462 to redundancy with other mitochondrial IAP binding proteins [114,115]. Interestingly, MOMP in
463 macrophages also causes IAP depletion but engages a different pro-inflammatory signalling
464 pathway [116,117]. In macrophages, MOMP-dependent depletion of IAPs activated caspase 8
465 (ref. [118,119]). Caspase 8 activity promoted the maturation of the pro-inflammatory cytokine
466 IL-1β [116,117]. By demonstrating caspase 8 activation downstream of MOMP, these studies
467 also reveal a novel means of crosstalk between the intrinsic and extrinsic apoptotic
468 signalling pathways. In parallel, the NLRP3 inflammasome **[G]** is also activated downstream
469 of MOMP causing caspase 1-dependent IL-1β maturation [116,117]. In this context, the NLRP3
470 inflammasome is activated by apoptotic caspase-dependent potassium efflux[120].
471
472 A final aspect of MOMP-induced inflammation relates to its recently described role
473 in the release of mitochondrial double stranded RNA (dsRNA) – a potent trigger of an anti-
474 viral interferon response [120]. Because of its circular structure, bi-directional transcription of
475 the mtDNA genome generates long dsRNAs. Normally, these dsRNAs are degraded by a
476 protein complex called the RNA degradosome **[G]** . Inhibition of RNA degradosome
477 components causes accumulation of cytosolic dsRNAs that bind an adaptor molecule MDA5.
478 MDA5 then activates the mitochondria bound protein MAVS, which subsequently
479 oligomerizes and activates NF-κB and IRF3 to induce an interferon response. Supporting the
480 relevance of this pathway in vivo, patients bearing a hypomorphic mutation in
481 polyribonucleotide nucleotidyl transferase 1 (PNPT1), an exoribonuclease involved in
482 mitochondrial dsRNA breakdown and an RNA degradosome component, display increased
483 markers of immune activation. Mitochondrial release of dsRNA requires either BAX or BAK,
484 possibly engaging the same macropore-based mechanism described for mtDNA [120].
485
486 *[H2] Counteracting MOMP-induced inflammation.*
487 Although MOMP can engage a plethora of inflammatory signalling pathways, in most
488 cases mitochondrial apoptosis is non-inflammatory. How can this be reconciled? The likely

main reason is that MOMP simultaneously activates apoptotic caspases to effectively quench inflammation (**Figure 5**). Apoptotic caspase function inhibits inflammation at multiple-levels. Firstly, inflammatory signalling components including MAVS, cGAS and IRF3 are directly cleaved (and inactivated) by apoptotic caspases [121]. Secondly, apoptotic caspase function inhibits many processes, including protein translation and canonical protein secretory pathways to prevent the production and release of inflammatory cytokines and thereby suppressing inflammation [6]. Finally, caspase activity causes rapid cell death that is coupled with caspase-dependent generation of "find-me" and "eat-me" signals **[G]** [122]. These signals recruit phagocytic cells to engulf and remove dying apoptotic cells before they can release any pro-inflammatory molecules. Nevertheless, caspase activity may not absolutely essential to curb MOMP-driven inflammation. For instance, on some genetic backgrounds *Caspase-3*$^{-/-}$ or *Apaf-1*$^{-/-}$ mice can survive to adulthood without an obvious hyper-inflammatory phenotype [123,124]. A potential explanation for lack of inflammation is that MOMP also engages additional caspase-independent anti-inflammatory mechanisms. One means is through MOMP-dependent release of PNPT1 from the mitochondrial intermembrane space, which causes global mRNA degradation and likely includes degradation of inflammatory transcripts [125]. Finally, MOMP engages autophagy, which supports autophagic sequestration of defective, permeabilized mitochondria. Autophagy also inhibits the secretion of specific pro-inflammatory cytokines such as IFN-β (**Figure 5**)[126].

Because MOMP normally engages anti-inflammatory caspase activity, when would the inflammatory consequences of MOMP manifest? Tracking back to our discussion of minority MOMP and pathogen immunity, minority MOMP has been shown to trigger inflammation under caspase-proficient conditions; in this setting, MOMP-induced inflammation overrides anti-inflammatory signals associated with caspase activity [95]. This implies that MOMP has a wide potential to drive inflammation, in particular in cell types exhibiting limited potential to engage caspase activity, such as cardiomyocytes (which show reduced APAF-1 expression) or sympathetic neurons (which are characterized by increased expression of the caspase inhibitor XIAP) [127,128]. Mitochondrial apoptosis in these cells may thus potentially have deleterious consequences. In line with this, recent studies have shown that inflammatory cGAS–STING signalling contributes to pathology observed during cardiac infarction [129]. Whether MOMP drives this inflammatory phenotype is not known, but in

support of this idea, myocardial specific deletion of anti-apoptotic protein MCL-1 — leading to increased apoptotic potential — has previously been shown to cause heart failure associated with inflammation [130].

In cancer therapy, intense interest surrounds making cancer cell death immunogenic in order to engage anti-tumour immunity [131]. Cell death is typically immunogenic through two distinct, though not mutually exclusive, means: release of inflammatory molecules (e.g. ATP, DNA) collectively referred to as damage-associated molecular patterns (DAMPs) from dying cells or, active engagement of pro-inflammatory signalling in the dying cell [132]. Unleashing pro-inflammatory effects of apoptosis can be achieved by caspase inhibition, resulting in caspase-independent cell death. As shown in cancer cells, this immunogenic type of apoptosis requires NF-κB activation in the dying cell [111]. Direct comparison of therapeutically inducing caspase-independent cell death versus canonical apoptosis demonstrated that, by engaging anti-tumour immunity, caspase-independent cell death is much more effective than apoptosis in clearing cancer cells, often leading to tumour regression. This suggests that inhibiting apoptotic caspase function may be beneficial in cancer treatment [111]. Supporting this idea, previous reports have shown that caspase inhibitors can have anti-tumour effects [133,134]. By eliciting an IFN response, targeting mitochondrial apoptotic caspase activity may also have anti-viral activity. Indeed, genetic inhibition of caspase function enhances anti-viral immunity that requires IFN signalling [101,121]. Moreover, emricasan, a clinically applicable pan-caspase inhibitor, was recently found to inhibit Zika virus infection, potentially by eliciting an IFN-response [135].

[H1] Mitochondria beyond apoptosis

Mitochondria are central initiators of the intrinsic pathway of apoptosis, but they may also contribute to other forms of programmed cell death (**Figure 6**). However, in these cases their participation is less defined and not necessarily essential.

[H2] Mitochondria can support necroptotic signalling.

Necroptosis is a regulated caspase-independent form of cell death that shares morphological and inflammatory characteristics with an unregulated, passive form of cell

552 death called necrosis[136]. Aberrant levels of necroptosis have been implicated in various
553 inflammatory diseases and ischaemic injury **[G]** , making this cell death modality an
554 important therapeutic target. Different stimuli, including viral infection and Toll receptor **[G]**
555 signalling, can induce necroptosis, but it is best characterised in the context of TNF
556 signalling. In a simplified model, under caspase 8 deficiency, TNF receptor engagement leads
557 to activation of receptor interacting protein kinase-1 (RIPK1) and RIPK3 causing the
558 formation of the necrosome **[G]**. RIPK3 phosphorylates mixed-lineage kinase domain-like
559 pseudokinase (MLKL) leading to its activation [136]. Active, oligomerized MLKL permeabilizes
560 the plasma membrane, killing the cell.
561 Do mitochondria have a role in necroptosis? Using a method of enforced mitophagy
562 to deplete mitochondria, forced activation of RIPK3 by chemically-induced dimerization has
563 shown that necroptosis executes with the same kinetics, irrespective of mitochondria,
564 consistent with activation of MLKL being the executioner mechanism of necroptosis [137]
565 (**Figure 6**). Nevertheless, at least in some cell types, mitochondrial ROS facilitate the
566 initiation of necroptosis by promoting RIPK1 autophosphorylation, leading to its activation
567 and necrosome formation [138,139]. In a feed-forward manner, RIPK3 kinase activates the
568 pyruvate dehydrogenase complex, leading to enhanced aerobic respiration and associated
569 increased ROS generation [140] (**Figure 6**). Because levels of ROS may be an important
570 determinant as to whether a cell initiates necroptosis, progressive mitochondrial
571 dysfunction, for example observed during ageing, may increase the propensity of cells to
572 undergo necroptosis.
573
574 *[H2] Interplay between mitochondrial apoptosis and pyroptosis.*
575 Pyroptosis is an inflammatory-type of regulated cell death driven by the
576 inflammatory caspases 1, 4, 5, and 11 [141]. Primarily serving as an innate immune response to
577 intracellular pathogens,-pyroptosis is executed by caspase-dependent cleavage of GSDMD
578 [142,143]. Initiation of pyroptosis requires inflammatory caspase activation, which occurs on
579 various signalling platforms that are collectively referred to as inflammasomes. During
580 pyroptosis, the amino-terminal GSDMD cleavage fragment permeabilizes the plasma
581 membrane leading to the release of pro-inflammatory cytokines including IL-1β and IL-18.
582

583 Mitochondria lose function prior to GSDMD-dependent plasma membrane rupture,
584 however there is little evidence that they play an important role in pyroptosis [144].
585 Nevertheless, extensive crosstalk exists between pyroptosis and mitochondrial apoptosis
586 (**Figure 6**). Firstly, as discussed previously, the inflammasome generated GSDMD amino-
587 terminal cleavage fragment can induce MOMP causing caspase3 activation [56]. Secondly, in
588 cells expressing low amounts of GSDMD, rather than pyroptosis, caspase 1 activation leads
589 to mitochondrial apoptosis [145], which is, at least in part, due to caspase 1-dependent
590 cleavage and activation of the BH3-only protein BID. Finally, mitochondrial apoptosis has
591 also been shown to initiate activation of the NLRP3-inflammasome leading to caspase 1
592 activity [146]. This requires caspase 3-dependent cleavage of a potassium channel forming
593 glycoprotein, pannexin-1, which activates the channel and causes potassium efflux from the
594 cell that promotes inflammasome assembly (**Figure 6**). Although the physiological
595 significance of crosstalk between different cell death modalities is currently unclear, it
596 emphasises that individual types of cell death cannot be viewed in isolation.
597
598 *[H2] Mitochondria, ROS and membrane peroxidation in ferroptosis.*
599 Ferroptosis is another pro-inflammatory cell death modality, which is triggered by
600 lipid peroxides that kill the cell by attacking lipid membranes leading to loss of cell integrity
601 [147,148]. As the name suggests, iron plays a crucial role in this process, as it is required for the
602 Fenton reaction **[G]** responsible for lipid peroxidation. Under normal circumstances,
603 peroxidised lipids are converted to lipid alcohols by glutathione peroxidase 4 (GPX4), which
604 inactivates these harmful peroxides. GPX4 requires glutathione **[G]** as cofactor to convert
605 peroxidised lipids to lipid alcohols and glutathione, in turn, requires cysteine. Transport of
606 cysteine (via cystine, an oxidized cysteine dimer) into the cells is driven by the export of
607 glutamate via System X_c^-, a mechanism that can be inhibited by a small molecule inhibitor
608 called erastin. Blocking System X_c^- with erastin therefore leads to decreased levels of
609 glutathione, and subsequently impaired neutralization of lipid peroxides by GPX4 (ref. [149]).
610
611 A role for mitochondria in regulating ferroptosis is contentious. For instance,
612 ferroptosis sensitivity has been found to be unaffected by loss of mtDNA or indeed removal
613 of mitochondria [148,150]. Nevertheless, in some instances mitochondria can contribute to
614 ferroptosis, which is mainly related to the generation of ROS (**Figure 6**). For example,

mitochondrial (as well as cytosolic) ferritin **[G]** chelates iron and therefore prevents accumulation of free iron and iron-dependent lipid peroxidation by Fenton reaction **[G]** [151]. Along similar lines, the increase in free iron — as result of haeme **[G]** degradation — was shown to drive ferroptosis in vivo in mice, in apoptosis and/or necroptosis deficient cardiomyocytes exposed to DNA-damaging agent doxorubicin or ischaemia/reperfusion [152]. In this case, the excess free iron accumulated in mitochondria and caused lipid peroxidation of their membranes (**Figure 6**). Another way of lipid peroxide accumulation in the mitochondria is during cysteine deprivation, which promotes glutaminolysis, and therefore potently enhances mitochondrial respiration (by stimulating the activity of the tricarboxylic acid cycle). This leads to mitochondrial hyperpolarisation and increased production of ROS, which was shown to promote lipid peroxidation and the induction of ferroptosis[153].

[H1] Conclusions and perspectives

In this Review we have discussed the central role of mitochondria in the apoptotic cell death. Beyond discussing the well-established roles in the execution of cell dismantling via apoptotic signalling, we aimed to highlight the surprising new role of mitochondria as pro-inflammatory signalling hubs during apoptosis. Together with recent findings that cells can tolerate limited MOMP, this emerging role suggests that apoptotic signalling may have non-lethal functions.

Going forward, a key area of research will be to define the occurrence and roles of MOMP-induced inflammation in health and disease. This will require further understanding of how MOMP engages both pro- and anti-inflammatory effects and how they interplay with each other. It will be interesting to address why these two opposing effects of MOMP coexist. One possibility is that the pro-inflammatory effects of MOMP evolved specifically to support innate immune responses to pathogen invasion. For instance, viruses can encode caspase inhibitors, and in this scenario induction of mitochondrial apoptosis by viruses could serve to elicit an anti-viral interferon response.

The finding that MOMP can occur in the absence of cells death opens further research questions. As we have discussed, there is support for non-lethal apoptotic signalling, nevertheless this evidence comes from in vitro experiments and the significance

of non-lethal apoptotic signalling in vivo is currently lacking. Key to investigating this problem will be designing a way to mark mammalian cells in vivo that have undergone minority MOMP resulting in sub-lethal caspase activity using genetically tractable reporter systems, similar to analogous approaches in *Drosophila melanogaster* [154]. On a mechanistic level , a crucial question will be to understand why some mitochondria selectively undergo MOMP since the mechanisms underlying this heterogeneity in MOMP are completely unknown at present.

Therapeutic targeting of mitochondrial apoptosis has a great clinical potential in various diseases, best evidenced by the development of BH3-mimetics in oncology. We now have effective ways to sensitize cells to mitochondrial apoptosis (**Figure 7**). Promoting mitochondrial apoptosis, using BH3-mimetics and possibly other approaches (for example, small molecule BAX activators) may have utility in different settings including, but not limited to, cancer [3], fibrosis [155] and ageing [156]. Although our ability to therapeutically inhibit mitochondrial apoptosis trails behind the approaches to induce apoptosis, progress is being made with inhibitors of BAX/BAK-dependent apoptotic activity recently being described [157,158] that can promote neuroprotection in the context of neurodegenerative disease (**Figure 7**). Recent discoveries that the outcome of apoptotic cell death (inflammatory versus non-inflammatory) can be modulated following MOMP, for example, by caspase inhibition, also opens new ways to think about therapeutically targeting the mitochondrial apoptotic pathway to promote immune responses against malignant, infected or otherwise dysfunctional cells (**Figure 7**).

Finally, as we have discussed, mitochondria have also been implicated in other forms of regulated cell death including necroptosis, pyroptosis and ferroptosis, although their role in these types of cell death appears less crucial, or at least context dependent. Nevertheless, it is increasingly apparent that these different cell death modalities crosstalk with one another and this crosstalk involves mitochondria. Given that some forms of cell death can be more inflammatory than others, how death is initiated, propagated and finally executed can have important consequences in cellular homeostasis as well as in the various disease settings involving deregulation of cell death.

References

1 Mehta, M. M., Weinberg, S. E. & Chandel, N. S. Mitochondrial control of immunity: beyond ATP. *Nat Rev Immunol* **17**, 608-620, doi:10.1038/nri.2017.66 (2017).

2 Filippi, M. D. & Ghaffari, S. Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities. *Blood* **133**, 1943-1952, doi:10.1182/blood-2018-10-808873 (2019).

3 Merino, D. *et al.* BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. *Cancer Cell* **34**, 879-891, doi:10.1016/j.ccell.2018.11.004 (2018).

4 Roberts, A. W. *et al.* Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. *N Engl J Med* **374**, 311-322, doi:10.1056/NEJMoa1513257 (2016).

5 Tuzlak, S., Kaufmann, T. & Villunger, A. Interrogating the relevance of mitochondrial apoptosis for vertebrate development and postnatal tissue homeostasis. *Genes Dev* **30**, 2133-2151, doi:10.1101/gad.289298.116 (2016).

6 Julien, O. & Wells, J. A. Caspases and their substrates. *Cell Death Differ* **24**, 1380-1389, doi:10.1038/cdd.2017.44 (2017).

7 Boatright, K. M. *et al.* A unified model for apical caspase activation. *Mol Cell* **11**, 529-541 (2003).

8 Pop, C., Timmer, J., Sperandio, S. & Salvesen, G. S. The apoptosome activates caspase-9 by dimerization. *Mol Cell* **22**, 269-275, doi:10.1016/j.molcel.2006.03.009 (2006).

9 Wu, C. C. *et al.* The Apaf-1 apoptosome induces formation of caspase-9 homo- and heterodimers with distinct activities. *Nat Commun* **7**, 13565, doi:10.1038/ncomms13565 (2016).

10 McCarthy, N. J., Whyte, M. K., Gilbert, C. S. & Evan, G. I. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. *J Cell Biol* **136**, 215-227, doi:10.1083/jcb.136.1.215 (1997).

11 Xiang, J., Chao, D. T. & Korsmeyer, S. J. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. *Proc Natl Acad Sci U S A* **93**, 14559-14563, doi:10.1073/pnas.93.25.14559 (1996).

12 Amarante-Mendes, G. P. *et al.* Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. *Cell Death Differ* **5**, 298-306, doi:10.1038/sj.cdd.4400354 (1998).

13 Cecconi, F., Alvarez-Bolado, G., Meyer, B. I., Roth, K. A. & Gruss, P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. *Cell* **94**, 727-737 (1998).

14 Yoshida, H. *et al.* Apaf1 is required for mitochondrial pathways of apoptosis and brain development. *Cell* **94**, 739-750 (1998).

15 Kuida, K. *et al.* Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. *Cell* **94**, 325-337 (1998).

16 Ke, F. F. S. *et al.* Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK. *Cell* **173**, 1217-1230 e1217, doi:10.1016/j.cell.2018.04.036 (2018).

This study affirms an important role for mitochondrial apoptosis in embryonic development but, surprisingly, shows that some apoptosis-deficient mice can survive to adulthood.

17 Lindsten, T. *et al.* The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. *Mol Cell* **6**, 1389-1399 (2000).

18 Lakhani, S. A. *et al.* Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. *Science* **311**, 847-851, doi:10.1126/science.1115035 (2006).

19 Goldstein, J. C., Waterhouse, N. J., Juin, P., Evan, G. I. & Green, D. R. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. *Nat Cell Biol* **2**, 156-162, doi:10.1038/35004029 (2000).

20 Lartigue, L. *et al.* Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. *Mol Biol Cell* **20**, 4871-4884, doi:10.1091/mbc.E09-07-0649 (2009).

21 Wei, M. C. *et al.* Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* **292**, 727-730, doi:10.1126/science.1059108 (2001).

22 Sarosiek, K. A. *et al.* BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. *Mol Cell* **51**, 751-765, doi:10.1016/j.molcel.2013.08.048 (2013).

23 Lopez, J. *et al.* Mito-priming as a method to engineer Bcl-2 addiction. *Nat Commun* **7**, 10538, doi:10.1038/ncomms10538 (2016).

24 Lauterwasser, J. *et al.* The porin VDAC2 is the mitochondrial platform for Bax retrotranslocation. *Sci Rep* **6**, 32994, doi:10.1038/srep32994 (2016).

25 Naghdi, S., Varnai, P. & Hajnoczky, G. Motifs of VDAC2 required for mitochondrial Bak import and tBid-induced apoptosis. *Proc Natl Acad Sci U S A* **112**, E5590-5599, doi:10.1073/pnas.1510574112 (2015).

26 Chin, H. S. *et al.* VDAC2 enables BAX to mediate apoptosis and limit tumor development. *Nat Commun* **9**, 4976, doi:10.1038/s41467-018-07309-4 (2018).

27 Edlich, F. *et al.* Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. *Cell* **145**, 104-116, doi:10.1016/j.cell.2011.02.034 (2011).

28 Todt, F. *et al.* Differential retrotranslocation of mitochondrial Bax and Bak. *EMBO J* **34**, 67-80, doi:10.15252/embj.201488806 (2015).

29 Schellenberg, B. *et al.* Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. *Mol Cell* **49**, 959-971, doi:10.1016/j.molcel.2012.12.022 (2013).

30 Letai, A. *et al.* Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. *Cancer Cell* **2**, 183-192 (2002).

31 Czabotar, P. E. *et al.* Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. *Cell* **152**, 519-531, doi:10.1016/j.cell.2012.12.031 (2013).

32 Moldoveanu, T. *et al.* BID-induced structural changes in BAK promote apoptosis. *Nat Struct Mol Biol* **20**, 589-597, doi:10.1038/nsmb.2563 (2013).

33 Leshchiner, E. S., Braun, C. R., Bird, G. H. & Walensky, L. D. Direct activation of full-length proapoptotic BAK. *Proc Natl Acad Sci U S A* **110**, E986-995, doi:10.1073/pnas.1214313110 (2013).

34 Brouwer, J. M. *et al.* Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design. *Mol Cell* **68**, 659-672 e659, doi:10.1016/j.molcel.2017.11.001 (2017).
35 Gavathiotis, E. *et al.* BAX activation is initiated at a novel interaction site. *Nature* **455**, 1076-1081, doi:10.1038/nature07396 (2008).
36 Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H. & Walensky, L. D. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. *Mol Cell* **40**, 481-492, doi:10.1016/j.molcel.2010.10.019 (2010).
37 Reyna, D. E. *et al.* Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. *Cancer Cell* **32**, 490-505 e410, doi:10.1016/j.ccell.2017.09.001 (2017).
38 Dengler, M. A. *et al.* BAX Activation: Mutations Near Its Proposed Non-canonical BH3 Binding Site Reveal Allosteric Changes Controlling Mitochondrial Association. *Cell Rep* **27**, 359-373 e356, doi:10.1016/j.celrep.2019.03.040 (2019).
39 Chen, H. C. *et al.* An interconnected hierarchical model of cell death regulation by the BCL-2 family. *Nat Cell Biol* **17**, 1270-1281, doi:10.1038/ncb3236 (2015).
40 Dewson, G. *et al.* Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. *Mol Cell* **36**, 696-703, doi:10.1016/j.molcel.2009.11.008 (2009).
41 Dewson, G. *et al.* To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. *Mol Cell* **30**, 369-380, doi:10.1016/j.molcel.2008.04.005 (2008).
42 Dewson, G. *et al.* Bax dimerizes via a symmetric BH3:groove interface during apoptosis. *Cell Death Differ* **19**, 661-670, doi:10.1038/cdd.2011.138 (2012).
43 Subburaj, Y. *et al.* Bax monomers form dimer units in the membrane that further self-assemble into multiple oligomeric species. *Nat Commun* **6**, 8042, doi:10.1038/ncomms9042 (2015).
44 Bleicken, S. *et al.* Molecular details of Bax activation, oligomerization, and membrane insertion. *J Biol Chem* **285**, 6636-6647, doi:10.1074/jbc.M109.081539 (2010).
45 Gillies, L. A. *et al.* Visual and functional demonstration of growing Bax-induced pores in mitochondrial outer membranes. *Mol Biol Cell* **26**, 339-349, doi:10.1091/mbc.E13-11-0638 (2015).
46 Bleicken, S., Landeta, O., Landajuela, A., Basanez, G. & Garcia-Saez, A. J. Proapoptotic Bax and Bak proteins form stable protein-permeable pores of tunable size. *J Biol Chem* **288**, 33241-33252, doi:10.1074/jbc.M113.512087 (2013).
47 Salvador-Gallego, R. *et al.* Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores. *EMBO J* **35**, 389-401, doi:10.15252/embj.201593384 (2016).

Bleicken et al. and Salvador-Gallego et al. use super-resolution micropscopy to visualise, for the first time, BAX pores on the mitochondrial outer membrane.

48 Grosse, L. *et al.* Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. *EMBO J* **35**, 402-413, doi:10.15252/embj.201592789 (2016).
49 Llambi, F. *et al.* BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. *Cell* **165**, 421-433, doi:10.1016/j.cell.2016.02.026 (2016).

50 Einsele-Scholz, S. *et al.* Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak. *J Cell Sci* **129**, 2213-2223, doi:10.1242/jcs.181727 (2016).

Together with Llambi et al. this study demonstrates that BOK can mediate MOMP and apoptosis in the absence of BAX and BAK.

51 Fernandez-Marrero, Y. *et al.* The membrane activity of BOK involves formation of large, stable toroidal pores and is promoted by cBID. *FEBS J* **284**, 711-724, doi:10.1111/febs.14008 (2017).

52 Zheng, J. H. *et al.* Intrinsic Instability of BOK Enables Membrane Permeabilization in Apoptosis. *Cell Rep* **23**, 2083-2094 e2086, doi:10.1016/j.celrep.2018.04.060 (2018).

53 Ke, F. *et al.* BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. *Cell Death Differ* **19**, 915-925, doi:10.1038/cdd.2011.210 (2012).

54 Wang, Y. *et al.* Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature* **547**, 99-103, doi:10.1038/nature22393 (2017).

55 Rogers, C. *et al.* Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. *Nat Commun* **8**, 14128, doi:10.1038/ncomms14128 (2017).

56 Rogers, C. *et al.* Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Nat Commun* **10**, 1689, doi:10.1038/s41467-019-09397-2 (2019).

57 Rehm, M., Dussmann, H. & Prehn, J. H. Real-time single cell analysis of Smac/DIABLO release during apoptosis. *J Cell Biol* **162**, 1031-1043, doi:10.1083/jcb.200303123 (2003).

58 Lartigue, L. *et al.* An intracellular wave of cytochrome c propagates and precedes Bax redistribution during apoptosis. *J Cell Sci* **121**, 3515-3523, doi:10.1242/jcs.029587 (2008).

59 Bhola, P. D., Mattheyses, A. L. & Simon, S. M. Spatial and temporal dynamics of mitochondrial membrane permeability waves during apoptosis. *Biophys J* **97**, 2222-2231, doi:10.1016/j.bpj.2009.07.056 (2009).

60 Rehm, M. *et al.* Dynamics of outer mitochondrial membrane permeabilization during apoptosis. *Cell Death Differ* **16**, 613-623, doi:10.1038/cdd.2008.187 (2009).

61 Cheng, X. & Ferrell, J. E., Jr. Apoptosis propagates through the cytoplasm as trigger waves. *Science* **361**, 607-612, doi:10.1126/science.aah4065 (2018).

62 Garcia-Perez, C. *et al.* Bid-induced mitochondrial membrane permeabilization waves propagated by local reactive oxygen species (ROS) signaling. *Proc Natl Acad Sci U S A* **109**, 4497-4502, doi:10.1073/pnas.1118244109 (2012).

63 Munoz-Pinedo, C. *et al.* Different mitochondrial intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in duration. *Proc Natl Acad Sci U S A* **103**, 11573-11578, doi:10.1073/pnas.0603007103 (2006).

64 Scorrano, L. *et al.* A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. *Dev Cell* **2**, 55-67 (2002).

65 Cogliati, S. *et al.* Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. *Cell* **155**, 160-171, doi:10.1016/j.cell.2013.08.032 (2013).

66 Yamaguchi, R. *et al.* Opa1-mediated cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak oligomerization. *Mol Cell* **31**, 557-569, doi:10.1016/j.molcel.2008.07.010 (2008).
67 Frank, S. *et al.* The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. *Dev Cell* **1**, 515-525 (2001).
68 Frezza, C. *et al.* OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. *Cell* **126**, 177-189, doi:10.1016/j.cell.2006.06.025 (2006).
69 van der Laan, M., Horvath, S. E. & Pfanner, N. Mitochondrial contact site and cristae organizing system. *Curr Opin Cell Biol* **41**, 33-42, doi:10.1016/j.ceb.2016.03.013 (2016).
70 Prudent, J. *et al.* MAPL SUMOylation of Drp1 Stabilizes an ER/Mitochondrial Platform Required for Cell Death. *Mol Cell* **59**, 941-955, doi:10.1016/j.molcel.2015.08.001 (2015).
71 Pernas, L. & Scorrano, L. Mito-Morphosis: Mitochondrial Fusion, Fission, and Cristae Remodeling as Key Mediators of Cellular Function. *Annu Rev Physiol* **78**, 505-531, doi:10.1146/annurev-physiol-021115-105011 (2016).
72 Parone, P. A. *et al.* Inhibiting the mitochondrial fission machinery does not prevent Bax/Bak-dependent apoptosis. *Mol Cell Biol* **26**, 7397-7408, doi:10.1128/MCB.02282-05 (2006).
73 Estaquier, J. & Arnoult, D. Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis. *Cell Death Differ* **14**, 1086-1094, doi:10.1038/sj.cdd.4402107 (2007).
74 Jiang, X., Jiang, H., Shen, Z. & Wang, X. Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis. *Proc Natl Acad Sci U S A* **111**, 14782-14787, doi:10.1073/pnas.1417253111 (2014).
75 Korwitz, A. *et al.* Loss of OMA1 delays neurodegeneration by preventing stress-induced OPA1 processing in mitochondria. *J Cell Biol* **212**, 157-166, doi:10.1083/jcb.201507022 (2016).
76 Otera, H., Miyata, N., Kuge, O. & Mihara, K. Drp1-dependent mitochondrial fission via MiD49/51 is essential for apoptotic cristae remodeling. *J Cell Biol* **212**, 531-544, doi:10.1083/jcb.201508099 (2016).
77 Sun, M. G. *et al.* Correlated three-dimensional light and electron microscopy reveals transformation of mitochondria during apoptosis. *Nat Cell Biol* **9**, 1057-1065, doi:10.1038/ncb1630 (2007).
78 Colell, A. *et al.* GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. *Cell* **129**, 983-997, doi:10.1016/j.cell.2007.03.045 (2007).
79 Tait, S. W. *et al.* Resistance to caspase-independent cell death requires persistence of intact mitochondria. *Dev Cell* **18**, 802-813, doi:10.1016/j.devcel.2010.03.014 (2010).
80 Deshmukh, M. & Johnson, E. M., Jr. Evidence of a novel event during neuronal death: development of competence-to-die in response to cytoplasmic cytochrome c. *Neuron* **21**, 695-705 (1998).
81 Martinou, I. *et al.* The release of cytochrome c from mitochondria during apoptosis of NGF-deprived sympathetic neurons is a reversible event. *J Cell Biol* **144**, 883-889, doi:10.1083/jcb.144.5.883 (1999).

82 Ichim, G. *et al.* Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. *Mol Cell* **57**, 860-872, doi:10.1016/j.molcel.2015.01.018 (2015).
This study found that MOMP can occur in a limited number of mitochondria within a cell causing caspase activation without cell death.

83 Gama, V. *et al.* The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells. *Sci Signal* **7**, ra67, doi:10.1126/scisignal.2005309 (2014).

84 Malladi, S., Challa-Malladi, M., Fearnhead, H. O. & Bratton, S. B. The Apaf-1*procaspase-9 apoptosome complex functions as a proteolytic-based molecular timer. *EMBO J* **28**, 1916-1925, doi:10.1038/emboj.2009.152 (2009).

85 Kavanagh, E., Rodhe, J., Burguillos, M. A., Venero, J. L. & Joseph, B. Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia. *Cell Death Dis* **5**, e1565, doi:10.1038/cddis.2014.514 (2014).

86 Gonzalvez, F. *et al.* TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. *Mol Cell* **48**, 888-899, doi:10.1016/j.molcel.2012.09.031 (2012).

87 Weber, G. F. & Menko, A. S. The canonical intrinsic mitochondrial death pathway has a non-apoptotic role in signaling lens cell differentiation. *J Biol Chem* **280**, 22135-22145, doi:10.1074/jbc.M414270200 (2005).

88 Ichim, G. & Tait, S. W. A fate worse than death: apoptosis as an oncogenic process. *Nat Rev Cancer* **16**, 539-548, doi:10.1038/nrc.2016.58 (2016).

89 Liu, X. *et al.* Caspase-3 promotes genetic instability and carcinogenesis. *Mol Cell* **58**, 284-296, doi:10.1016/j.molcel.2015.03.003 (2015).

90 Lovric, M. M. & Hawkins, C. J. TRAIL treatment provokes mutations in surviving cells. *Oncogene* **29**, 5048-5060, doi:10.1038/onc.2010.242 (2010).

91 Miles, M. A. & Hawkins, C. J. Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine. *Cell Death Dis* **8**, e3062, doi:10.1038/cddis.2017.454 (2017).

92 Cartwright, I. M., Liu, X., Zhou, M., Li, F. & Li, C. Y. Essential roles of Caspase-3 in facilitating Myc-induced genetic instability and carcinogenesis. *Elife* **6**, doi:10.7554/eLife.26371 (2017).

93 Gong, Y. N., Crawford, J. C., Heckmann, B. L. & Green, D. R. To the edge of cell death and back. *FEBS J* **286**, 430-440, doi:10.1111/febs.14714 (2019).

94 McArthur, K. & Kile, B. T. Apoptotic Caspases: Multiple or Mistaken Identities? *Trends Cell Biol* **28**, 475-493, doi:10.1016/j.tcb.2018.02.003 (2018).

95 Brokatzky, D. *et al.* A non-death function of the mitochondrial apoptosis apparatus in immunity. *EMBO J* **38**, doi:10.15252/embj.2018100907 (2019).

96 Tang, H. L. *et al.* Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. *Mol Biol Cell* **23**, 2240-2252, doi:10.1091/mbc.E11-11-0926 (2012).

97 Sun, G. *et al.* A molecular signature for anastasis, recovery from the brink of apoptotic cell death. *J Cell Biol* **216**, 3355-3368, doi:10.1083/jcb.201706134 (2017).

98 Jiang, X. *et al.* A Small Molecule That Protects the Integrity of the Electron Transfer Chain Blocks the Mitochondrial Apoptotic Pathway. *Mol Cell* **63**, 229-239, doi:10.1016/j.molcel.2016.06.016 (2016).
99 Martin, S. J., Henry, C. M. & Cullen, S. P. A perspective on mammalian caspases as positive and negative regulators of inflammation. *Mol Cell* **46**, 387-397, doi:10.1016/j.molcel.2012.04.026 (2012).
100 Green, D. R. *Means to an end: apoptosis and other cell death mechanisms*. (Cold Spring Harbor Laboratory Press, 2010).
101 Rongvaux, A. *et al.* Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. *Cell* **159**, 1563-1577, doi:10.1016/j.cell.2014.11.037 (2014).
102 White, M. J. *et al.* Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. *Cell* **159**, 1549-1562, doi:10.1016/j.cell.2014.11.036 (2014).
Rongvaux et al. and White et al. demonstrate that under caspase inhibited conditions, MOMP activates cGAS–STING signalling dependent on mtDNA.

103 Ablasser, A. & Chen, Z. J. cGAS in action: Expanding roles in immunity and inflammation. *Science* **363**, doi:10.1126/science.aat8657 (2019).
104 Riley, J. S. *et al.* Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. *EMBO J* **37**, doi:10.15252/embj.201899238 (2018).
105 McArthur, K. *et al.* BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. *Science* **359**, doi:10.1126/science.aao6047 (2018).
106 Ader, N. R. *et al.* Molecular and topological reorganizations in mitochondrial architecture interplay during Bax-mediated steps of apoptosis. *Elife* **8**, doi:10.7554/eLife.40712 (2019).
Riley et al., McArthur et al. and Ader et al. describe the formation of BAX/BAK-dependent macropores on the mitochondrial outer membrane leading to inner mitochondrial membrane extrusion and mtDNA release.

107 Sliter, D. A. *et al.* Parkin and PINK1 mitigate STING-induced inflammation. *Nature* **561**, 258-262, doi:10.1038/s41586-018-0448-9 (2018).
108 West, A. P. *et al.* Mitochondrial DNA stress primes the antiviral innate immune response. *Nature* **520**, 553-557, doi:10.1038/nature14156 (2015).
109 Aarreberg, L. D. *et al.* Interleukin-1beta Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING. *Mol Cell* **74**, 801-815 e806, doi:10.1016/j.molcel.2019.02.038 (2019).
110 Zhong, Z. *et al.* New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. *Nature* **560**, 198-203, doi:10.1038/s41586-018-0372-z (2018).
111 Giampazolias, E. *et al.* Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency. *Nat Cell Biol* **19**, 1116-1129, doi:10.1038/ncb3596 (2017).
This study shows that under caspase-inhibited conditions MOMP elicits anti-tumour immunity, thereby supporting the rationale for inhibiting apoptotic caspase function in cancer.

112 Vince, J. E. *et al.* IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. *Cell* **131**, 682-693, doi:10.1016/j.cell.2007.10.037 (2007).

113 Varfolomeev, E. *et al.* IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell* **131**, 669-681, doi:10.1016/j.cell.2007.10.030 (2007).
114 Verhagen, A. M. *et al.* Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. *Cell Death Differ* **14**, 348-357, doi:10.1038/sj.cdd.4402001 (2007).
115 Zhuang, M., Guan, S., Wang, H., Burlingame, A. L. & Wells, J. A. Substrates of IAP ubiquitin ligases identified with a designed orthogonal E3 ligase, the NEDDylator. *Mol Cell* **49**, 273-282, doi:10.1016/j.molcel.2012.10.022 (2013).
116 Chauhan, D. *et al.* BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1beta Maturation in Macrophages. *Cell Rep* **25**, 2354-2368 e2355, doi:10.1016/j.celrep.2018.10.087 (2018).
117 Vince, J. E. *et al.* The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1beta Activation. *Cell Rep* **25**, 2339-2353 e2334, doi:10.1016/j.celrep.2018.10.103 (2018).
118 Tenev, T. *et al.* The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. *Mol Cell* **43**, 432-448, doi:10.1016/j.molcel.2011.06.006 (2011).
119 Feoktistova, M. *et al.* cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. *Mol Cell* **43**, 449-463, doi:10.1016/j.molcel.2011.06.011 (2011).
120 Dhir, A. *et al.* Mitochondrial double-stranded RNA triggers antiviral signalling in humans. *Nature* **560**, 238-242, doi:10.1038/s41586-018-0363-0 (2018).
121 Ning, X. *et al.* Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3. *Mol Cell* **74**, 19-31 e17, doi:10.1016/j.molcel.2019.02.013 (2019).
122 Arandjelovic, S. & Ravichandran, K. S. Phagocytosis of apoptotic cells in homeostasis. *Nat Immunol* **16**, 907-917, doi:10.1038/ni.3253 (2015).
123 Leonard, J. R., Klocke, B. J., D'Sa, C., Flavell, R. A. & Roth, K. A. Strain-dependent neurodevelopmental abnormalities in caspase-3-deficient mice. *J Neuropathol Exp Neurol* **61**, 673-677, doi:10.1093/jnen/61.8.673 (2002).
124 Honarpour, N. *et al.* Adult Apaf-1-deficient mice exhibit male infertility. *Dev Biol* **218**, 248-258, doi:10.1006/dbio.1999.9585 (2000).
125 Liu, X. *et al.* PNPT1 Release from Mitochondria during Apoptosis Triggers Decay of Poly(A) RNAs. *Cell* **174**, 187-201 e112, doi:10.1016/j.cell.2018.04.017 (2018).
126 Lindqvist, L. M. *et al.* Autophagy induced during apoptosis degrades mitochondria and inhibits type I interferon secretion. *Cell Death Differ* **25**, 782-794, doi:10.1038/s41418-017-0017-z (2018).
127 Potts, M. B., Vaughn, A. E., McDonough, H., Patterson, C. & Deshmukh, M. Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. *J Cell Biol* **171**, 925-930, doi:10.1083/jcb.200504082 (2005).
128 Potts, P. R., Singh, S., Knezek, M., Thompson, C. B. & Deshmukh, M. Critical function of endogenous XIAP in regulating caspase activation during sympathetic neuronal apoptosis. *J Cell Biol* **163**, 789-799, doi:10.1083/jcb.200307130 (2003).
129 King, K. R. *et al.* IRF3 and type I interferons fuel a fatal response to myocardial infarction. *Nat Med* **23**, 1481-1487, doi:10.1038/nm.4428 (2017).

130 Thomas, R. L. *et al.* Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. *Genes Dev* **27**, 1365-1377, doi:10.1101/gad.215871.113 (2013).
131 Messmer, M. N., Snyder, A. G. & Oberst, A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. *Cell Death Differ* **26**, 115-129, doi:10.1038/s41418-018-0214-4 (2019).
132 Yatim, N., Cullen, S. & Albert, M. L. Dying cells actively regulate adaptive immune responses. *Nat Rev Immunol* **17**, 262-275, doi:10.1038/nri.2017.9 (2017).
133 Kim, K. W., Moretti, L. & Lu, B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. *PLoS One* **3**, e2275, doi:10.1371/journal.pone.0002275 (2008).
134 Werthmoller, N., Frey, B., Wunderlich, R., Fietkau, R. & Gaipl, U. S. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. *Cell Death Dis* **6**, e1761, doi:10.1038/cddis.2015.129 (2015).
135 Xu, M. *et al.* Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. *Nat Med* **22**, 1101-1107, doi:10.1038/nm.4184 (2016).
136 Weinlich, R., Oberst, A., Beere, H. M. & Green, D. R. Necroptosis in development, inflammation and disease. *Nat Rev Mol Cell Biol* **18**, 127-136, doi:10.1038/nrm.2016.149 (2017).
137 Tait, S. W. *et al.* Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. *Cell Rep* **5**, 878-885, doi:10.1016/j.celrep.2013.10.034 (2013).
138 Schenk, B. & Fulda, S. Reactive oxygen species regulate Smac mimetic/TNFalpha-induced necroptotic signaling and cell death. *Oncogene* **34**, 5796-5806, doi:10.1038/onc.2015.35 (2015).
139 Zhang, Y. *et al.* RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome. *Nat Commun* **8**, 14329, doi:10.1038/ncomms14329 (2017).
140 Yang, Z. *et al.* RIP3 targets pyruvate dehydrogenase complex to increase aerobic respiration in TNF-induced necroptosis. *Nat Cell Biol* **20**, 186-197, doi:10.1038/s41556-017-0022-y (2018).
141 Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev Immunol* **16**, 407-420, doi:10.1038/nri.2016.58 (2016).
142 Kayagaki, N. *et al.* Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* **526**, 666-671, doi:10.1038/nature15541 (2015).
143 Shi, J. *et al.* Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* **526**, 660-665, doi:10.1038/nature15514 (2015).
Kayagaki et al. and Shi et al demonstrate that caspase cleavage of gasdermin D causes plasma membrane permeabilization and pyroptosis.

144 de Vasconcelos, N. M., Van Opdenbosch, N., Van Gorp, H., Parthoens, E. & Lamkanfi, M. Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. *Cell Death Differ* **26**, 146-161, doi:10.1038/s41418-018-0106-7 (2019).

145 Tsuchiya, K. *et al.* Caspase-1 initiates apoptosis in the absence of gasdermin D. *Nat Commun* **10**, 2091, doi:10.1038/s41467-019-09753-2 (2019).
146 Chen, K. W. *et al.* Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly. *EMBO J* **38**, doi:10.15252/embj.2019101638 (2019).
147 Stockwell, B. R. *et al.* Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell* **171**, 273-285, doi:10.1016/j.cell.2017.09.021 (2017).
148 Dixon, S. J. *et al.* Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* **149**, 1060-1072, doi:10.1016/j.cell.2012.03.042 (2012).
149 Yang, W. S. *et al.* Regulation of ferroptotic cancer cell death by GPX4. *Cell* **156**, 317-331, doi:10.1016/j.cell.2013.12.010 (2014).
150 Gaschler, M. M. *et al.* Determination of the Subcellular Localization and Mechanism of Action of Ferrostatins in Suppressing Ferroptosis. *ACS Chem Biol* **13**, 1013-1020, doi:10.1021/acschembio.8b00199 (2018).
151 Wang, Y. Q. *et al.* The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. *Front Aging Neurosci* **8**, 308, doi:10.3389/fnagi.2016.00308 (2016).
152 Fang, X. X. *et al.* Ferroptosis as a target for protection against cardiomyopathy. *P Natl Acad Sci USA* **116**, 2672-2680, doi:10.1073/pnas.1821022116 (2019).
153 Gao, M. H. *et al.* Role of Mitochondria in Ferroptosis. *Molecular Cell* **73**, 354-+, doi:10.1016/j.molcel.2018.10.042 (2019).
154 Ding, A. X. *et al.* CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. *Elife* **5**, doi:10.7554/eLife.10936 (2016).
155 Lagares, D. *et al.* Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. *Sci Transl Med* **9**, doi:10.1126/scitranslmed.aal3765 (2017).
156 Chang, J. *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat Med* **22**, 78-83, doi:10.1038/nm.4010 (2016).
157 Garner, T. P. *et al.* Small-molecule allosteric inhibitors of BAX. *Nat Chem Biol* **15**, 322-330, doi:10.1038/s41589-018-0223-0 (2019).

Garner et al. and Niu et al. describe the development of small molecular BAX,/BAK inhibitors that may serve as protoypes to develop therapeutic inhibitors of mitochondrial apoptosis.

158 Niu, X. *et al.* A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. *Cell Chem Biol* **24**, 493-506 e495, doi:10.1016/j.chembiol.2017.03.011 (2017).
159 Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. *Nat Rev Mol Cell Biol* **20**, 175-193, doi:10.1038/s41580-018-0089-8 (2019).
160 Llambi, F. *et al.* A unified model of mammalian BCL-2 protein family interactions at the mitochondria. *Mol Cell* **44**, 517-531, doi:10.1016/j.molcel.2011.10.001 (2011).
161 Pecot, J. *et al.* Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. *Cell Rep* **17**, 3347-3358, doi:10.1016/j.celrep.2016.11.064 (2016).
162 Liu, Q. *et al.* Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. *Elife* **8**, doi:10.7554/eLife.37689 (2019).

163 O'Neill, K. L., Huang, K., Zhang, J., Chen, Y. & Luo, X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. *Genes Dev* **30**, 973-988, doi:10.1101/gad.276725.115 (2016).
This study shows that in the absence of all known BH3-only proteins, inhibition of anti-apoptotic BCL-2 proteins is sufficient to activate BAX and BAK.

Acknowledgements

We thank Scott Dixon and Tudor Moldoveanu for discussion and critical input.

Research in our lab is supported by funding from Cancer Research UK (C40872/A20145) and Prostate Cancer UK (RIA17-ST2-002).

Author contributions

The authors contributed equally to all aspects of the article.

Competing interests

The authors declare no competing interests.

Publisher's note

Peer review information

Nature Reviews Molecular Cell Biology thanks P. Juin and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Display items

Box 1. BCL-2 protein-mediated regulation of mitochondrial apoptosis

BCL-2 protein-mediated regulation of cell death has recently been reviewed in-depth elsewhere[159], therefore here we present only an overview. The BCL-2 protein family comprises three subsets: the anti-apoptotic proteins, pro-apoptotic effectors and pro-apoptotic BH3-only proteins (see the figure). Following an apoptotic stress, BH3-only proteins are activated in different ways, for instance by transcriptional up-regulation (e.g. p53-mediated up-regulation of PUMA) or by post-translational modification (e.g. caspase 8-mediated cleavage of BID). They subsequently activate BAX and BAK, cause mitochondrial outer membrane permeabilization (MOMP) and apoptosis.

In healthy cells, anti-apoptotic BCL-2 proteins prevent MOMP by binding activated BAX and BAK effectors and BH3-only proteins [160]. This binding occurs via a hydrophobic groove, which interacts with the BH3-domain of pro-apoptotic BCL-2 proteins. Competitive disruption of this interaction forms the basis of pro-apoptotic activity of BH3-mimetics. Of note, efficiency of BH3-mimetics can be compromised by additional regulation of anti-apoptotic proteins, leading to drug resistance. For example, mitochondrial association of BCL-xL can increase its affinity for BH3-only proteins [161], whereas BIM has been found to encode an additional carboxy-terminal site that binds to anti-apoptotic BCL-2 proteins in a manner that is resistant to displacement by BH3 mimetics[162].

How exactly BAX and BAK become activated has been contentious. Two prominent models have been proposed: 1) the indirect activation model, where inhibition of anti-apoptotic BCL-2 proteins activates BAX and BAK and 2) direct model of activation where a subset of BH3-only proteins called direct activators (BID, BIM, PUMA) directly activate BAX and BAK. Distinguishing between these two models has proven challenging, in large part because direct activator BH3-only proteins also inhibit all anti-apoptotic BCL-2 proteins. Intriguingly, a recent study has found that in the absence of all known BH3-only proteins, inhibition of anti-apoptotic BCL-2 function using BH3-mimetics is sufficient to activate BAX and BAK leading to apoptosis [163]. This demonstrates that BH3-only proteins are dispensable for the direct activation of BAX and BAK, but it remains an open question as to how BAX and BAK can acquire active conformations in the absence of BH3-only proteins. BH, Bcl-2 homology domain; TMD, transmembrane domain.

Figure 1. Apoptotic signalling pathways Apoptosis can occur via two pathways: extrinsic and intrinsic. Extrinsic (also known as death receptor) apoptotic pathway involves the binding of a death receptor ligand to a member of the death receptor family (members of the tumor necrosis receptor superfamily). For example, Fas-ligand binding to Fas initiates apoptosis by recruiting the adaptor molecule FADD. FADD binds to and induces dimerization of the initiator caspase 8 leading to its activation. Active caspase 8 cleaves and activates the executioner caspases 3 and 7, leading to wide-scale cleavage of cellular components and rapid cell death. In the intrinsic (also known as mitochondrial) apoptotic pathway is induced

by a vast number of different stimuli (including DNA-damage, growth factor withdrawal, mitotic arrest), which cause activation of a BH3-only members of the BCL-2 protein family. BH3-only proteins inhibit anti-apoptotic BCL-2 proteins and activate effector pro-apoptotic BCL-2 proteins BAX and BAK leading to mitochondrial outer membrane permeabilization (MOMP). This allows the release of mitochondrial intermembrane space proteins that activate caspases, most importantly, cytochrome *c*. Cytochrome *c* binds to APAF-1 forming a heptameric structure called the apoptosome. This recruits and activates the initiator caspase 9 that activates caspase 3 and 7. MOMP also causes the release of proteins including SMAC and OMI that block the caspase inhibitor XIAP, facilitating apoptosis. Caspase 8-mediated cleavage and activation of BH3-only protein BID (to generate tBID) connects the extrinsic apoptotic pathway to the intrinsic pathway.

Figure 2. BAX/BAK-mediated mitochondrial outer membrane permeabilization

In healthy conditions, BAX, and to a lesser degree BAK, shuttle between the mitochondria and cytoplasm (step 1). During apoptosis, BAX and BAK can be directly activated by binding BH3-only proteins; this leads to their stabilization at the outer mitochondrial membrane (OMM) and their homodimerization (step 2). BAX/BAK dimers then further oligomerize forming higher-order multimers that generate lipid pores within the outer mitochondrial membrane causing mitochondrial outer membrane permeabilization (MOMP); this leads to the non-selective release of soluble intermembrane space proteins, such as cytochrome *c* from the intermembrane space; this release process has been suggested to be further facilitated by inner mitochondrial membrane (IMM) remodelling that involves opening of the mitochondrial cristae to allow robust release of cytochrome *c* (step 3). Over time, BAX/BAK-mediated pores expand forming macropores; this enables IMM extrusion through the OMM, whereupon it herniates and ruptures allowing the release of mitochondrial DNA (mtDNA) (step 4). Although the exact mechanism of IMM herniation and rupture is not known, dilution of the mitochondrial matrix and the associated increased pressure may play a role.

Figure 3. Differential levels of mitochondrial outer membrane permeabilization permit cell survival and unmask signalling functions

Apoptotic stresses can lead to incomplete mitochondrial outer membrane permeabilization (MOMP), which is compatible with cell survival. **a)** Cells induced to undergo apoptosis can survive under conditions of caspase inhibition. Cell survival in this context requires the presence of a subpopulation of intact mitochondria that did not undergo MOMP. Cell survival also depends on the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which supports high glycolytic activity and autophagy, thereby generating energy to prevent metabolic catastrophe and removing dysfunctional mitochondria that could instigate further damage. Through these mechanisms cells can survive long enough to allow the intact mitochondria to proliferate enabling cell survival. **b)** Sub-lethal stresses, for instance BH3-mimetic treatment, can cause only a subset of mitochondria to undergo MOMP — a condition known as minority MOMP. Minority MOMP can engage a limited, sub-lethal caspase activity, which is associated with DNA damage dependent on caspase-activated DNAse (CAD) and caspase 3- dependent release of endonuclease G (Endo G) from mitochondria. Such DNA damage can promote oncogenic transformation. Minority MOMP can also drive pro-inflammatory signalling in the absence of cell death, for instance by inducing CAD-dependent DNA damage, or by causing mtDNA release, both of which can drive pro-inflammatory signalling via cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) (see also Fig. 4).

Figure 4. Pro-inflammatory effects of mitochondrial outer membrane permeabilization
Mitochondrial outer membrane permeabilization (MOMP) can induce inflammation in multiple ways. **1:** Following MOMP, the outer membrane pores progressively widen enabling inner mitochondrial membrane extrusion and rupture. This allows mtDNA release into the cytosol whereupon it can engage cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) signalling, leading to pro-inflammatory interferon signalling. **2:** MOMP causes the proteasomal degradation of IAP proteins (inhibitors of apoptosis), which leads to upregulation of NIK kinase causing pro-inflammatory NF-κB signalling and activation of caspase 8, in turn causing maturation of pro-inflammatory IL-1β. **3:** Under conditions of defective degradation of mitochondrial double-stranded RNA (dsRNA), like knockdown of RNA degradosome components, dsRNA is released via an ill-defined mechanism from the mitochondria in a BAX/BAK-dependent manner. In the cytosol, dsRNA can bind adaptor

protein MDA5 that then binds MAVS, which subsequently oligomerizes and activates NF-κB and IRF3 to induce an interferon response.

Figure 5. Inhibition of mitochondrial outer membrane permeabilization-induced inflammation

Inflammatory signalling downstream of mitochondrial outer membrane permeabilization (MOMP) is regulated in multiple ways. Firstly, caspases inhibit multiple processes required for pro-inflammatory cytokine synthesis and secretion. This includes general downregulation of protein translation and canonical protein secretion to prevent the production and release of inflammatory cytokines. Caspases also directly cleave and inactivate various pro-inflammatory signalling molecules including cyclic GMP-AMP synthase (cGAS), MAVS and IRF3. Caspase activity also promotes the quick death and phagocytic removal of dying cells by invoking "find me" and "eat me" signals, limiting the time in which the dying cells can produce pro-inflammatory signalling molecules. Beyond the role of caspases, MOMP is associated with the release of RNA degradasome component polyribonucleotide nucleotidyl transferase 1 (PNPT1), which can cause global mRNA degradation, likely causing downregulation of inflammatory gene transcripts. MOMP also activates autophagy that sequesters permeabilized mitochondria and inhibits the release of pro-inflammatory IFN-β.

Figure 6. Mitochondria and non-apoptotic cell death

a) Necroptosis is a pro-inflammatory mode of cell death associated with the release of damage associated molecular patterns (DAMPs). Various treatments can trigger necroptosis, which is best characterised following tumor necrosis factor (TNF) treatment. Under caspase inhibition, TNF treatment leads to sequential phosphorylation (P) and activation of the kinases RIPK1 and RIPK3 and necrosome formation. The necrosome then phosphorylates and activates the pseudokinase MLKL, which translocates to and permeabilizes the plasma membrane, killing the cell. RIPK3 also activates the mitochondrial pyruvate dehydrogenase (PDH) complex, causing enhanced aerobic respiration and increased generation of reactive oxygen species (ROS). These mitochondria-derived ROS can feed-forward to enhance necrosome assembly and RIPK3 activity. **b)** Activation of

inflammasome complexes, for instance by intracellular pathogens, causes inflammatory caspase activation, which cleave pro-inflammatory cytokines IL-1β and IL-18, leading to their maturation. Inflammatory caspases also cleave and activate gasdermin D (GSDMD). Active GSDMD forms pores and permeabilizes the plasma membrane leading to pyroptotic cell death. Active GSDMD can also cause mitochondrial outer membrane permeabilization (MOMP). Additionally, inflammasome activity promotes MOMP through the cleavage and activation of the BH3-only protein BID. Downstream of MOMP, activation of caspase 3 leads to cleavage-dependent activation of the potassium channel forming glycoprotein pannexin-1. This causes potassium efflux from the cell, which promotes inflammasome assembly. **c)** Ferroptosis is triggered by oxidized lipids in reactions catalyzed with the help of iron and ROS (Fenton reaction). Defence against this reaction is provided by glutathione peroxidase 4 (GPX4), which inactivates harmful lipid peroxides One means of ferroptosis induction is via treatment with erastin, which blocks import of cysteine and interferes with GPX4 activity or via cysteine deprivation. Beyond affecting GPX4, cysteine deprivation also causes increased glutaminolysis, which feeds the mitochondrial tricarboxylic acid (TCA) cycle, thereby increasing mitochondrial respiration and in consequence augmenting levels of mitochondrial ROS. Iron is stored in various iron-binding proteins including ferritin and haeme-containing proteins, and mitochondria contribute to this storage. These iron-storing proteins are degraded under certain cell death-inducing conditions leading to iron release. Proximity of mitochondrial membranes to such sources of free iron and ROS makes them an important target for lipid oxidation associated with ferroptosis. ETC, electron transport chain.

Figure 7. Strategies to target mitochondrial apoptosis in disease

1: Apoptosis can be activated either through inhibition of anti-apoptotic BCL-2 proteins (with BH3-mimetics) or by directly activating BAX/BAK (for example, with small molecules). Such approaches have a proven use in oncology and have a clinical potential in the treatment of autoimmunity, fibrosis and ageing. **2:** Efficient inhibition of mitochondrial apoptosis can be achieved via blocking BAX and BAK (for example, with small molecules), which has a potential use in counteracting pathological cell loss, for instance in the context of neurodegenerative diseases or infection. **3:** Inhibition of caspase function following mitochondrial outer membrane permeabilization (MOMP; see also Fig. 3) has the potential

to turn apoptosis into an immunogenic type of cell death, which could be used to boost immune responses in anti-tumour and anti-viral therapies. **4:** Better understanding of the heterogeneity of MOMP and mechanisms of mitochondrial network recovery in the absence of cell death following MOMP could be used to promote cell survival in the context of cell loss in response to various insults, such as stroke or infarction.

Glossary

BH3-mimetics
Drugs modelled after the proapoptotic BH3 domain of BH3 only proteins that are used in cancer therapy

Death inducing signalling complex (DISC)
Complex consisting of death receptor, FADD and caspase 8 that can mediate apoptosis

SMAC (also called DIABLO)
Mitochondrial intermembrane space protein that upon MOMP binds to and inhibits XIAP

OMI (also called HtrA2)
Serine protease located within mitochondrial intermembrane space that binds to and inhibits XIAP following MOMP

XIAP
Protein that binds to and inhibits caspases 3, -7 and -9
ER associated degradation (ERAD)
Pathway that serves to degrade misfolded ER proteins by the proteasome, mitigating ER stress

Neoantigens
Newly generated antigens that, in cancer, usually arise from mutated genes

Type I interferon
Class of cytokines mediating inflammation

SMAC-mimetic compounds
Chemicals that were designed to phenocopy the IAP-binding and inhibitory properties of SMAC

NLRP3 inflammasome
Protein complex containing NLRP3 and caspase 1 that processes and activates inflammatory cytokines like IL-1 and IL-18

RNA degradasome
Multi-protein complex present in bacteria and mitochondria that degrades RNA

"find-me" and "eat-me" signals
Molecular signals used by dying cells to attract phagocytes; examples of find-me signals include ATP and lysophosphatidylcholine (LPC); the best characterised eat-me signal is phosphatidylserine (PS).

Ischaemic injury
Hypoxia-mediated injury due to diminished blood flow

Toll receptor
A class of protein receptors that serve a key role in innate immunity by sensing conserved molecules derived from microbes

Necrosome
Protein complex containing RIP1 and RIP3 kinases that promotes necroptotic cell death

Fenton reaction
Reaction of peroxides with iron to yield free radicals

Glutathione
Key cellular antioxidant that scavenges reactive oxygen species through reduction

Ferritin
Iron-binding protein that plays important roles in the storage and transport of iron throughout the body

Haeme
Iron-containing co-ordination complex present in haemoproteins such as haemoglobin, catalases and cytochrome *c*

eTOC

Mitochondria are key executioners of apoptosis. However, it has recently become clear that beyond driving apoptosis, mitochondria also contribute to pro-inflammatory signalling and other types of regulated cell death. These functions are relevant to disease and could be targeted in the treatment of, for example, degenerative disorders, infection and cancer.